|
Session 140-Poster Abstracts
Dyslipidemia and Fat Changes: ART Effects
Wednesday, 2-4 pm; Poster Hall |
| 719 |
Greater Postprandial LDL Cholesterol Excursions with Low-dose Ritonavir vs Raltegravir in HIV-uninfected Adults: A Randomized Study
K Samaras1, R Richardson2, and Andrew Carr*2
1Garvan Inst of Med Res, Sydney, Australia and 2Ctr for Applied Med Res, St Vincent’s Hosp, Sydney, Australia |
720
 |
Metabolic Profiles and Body Composition Changes in Treatment-naive HIV-infected Patients Treated with Raltegravir 400 mg Twice-daily vs Efavirenz 600 mg Each Bedtime Combination Therapy: 96-week Follow-up
Edwin DeJesus*1, C Cohen2, J Lennox3, A Lazzarin4, D Berger5, B Jin6, H Teppler6, B-Y Nguyen6, R Leavitt6, and P Sklar6
1Orlando Immunology Ctr, FL, US; 2Community Res Initiative of New England, Boston, MA, US; 3Emory Univ, Atlanta, GA, US; 4Univ Vita-Salute San Raffaele, Milan, Italy; 5Northstar Med Ctr, Chicago, IL, US; and 6Merck Res Labs, North Wales, PA, US |
721
|
Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with CDRV/r Monotherapy vs 2 NRTI + DRV/r in the MONOI–ANRS 136 Randomized Trial: Results at 48 Weeks
Marc-Antoine Valantin*1, P Flandre2, S Kolta3, C Duvivier4, M Algarte Genin2, D Ponscarme5, L Slama6, L Cuzin7, M Bentata8, and C Katlama1
1Hosp Pitie-Salpetriere, Paris, France; 2INSERM U943, Univ Pierre and Marie Curie, Paris, France; 3Hosp Cochin, Paris, France; 4Hosp Necker, Paris, France; 5Hosp Saint Louis, Paris, France; 6Hosp Tenon, Paris, France; 7Hosp Purpan, Toulouse, France; and 8Hosp Avicenne, Bobigny, France |
|
